KLOW is a blend label, not an FDA-approved drug name. Most current KLOW labels refer to an expanded GLOW-style blend: GHK-Cu, BPC-157, TB-500, and KPV in one vial.

Is KLOW the same as Klotho peptide?

Usually no. Most KLOW blend pages refer to BPC-157 + TB-500 + GHK-Cu + KPV. A separate body of research studies Klotho-derived peptides such as KP1, but that is a different scientific topic and not the same as a multi-peptide KLOW blend.

How do I reconstitute a KLOW 80 mg vial?

This is arithmetic, not a dose recommendation. If the vial is an 80 mg total blend labeled 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV, adding 4 mL bacteriostatic water gives 20 mg/mL total blend. On a 100-unit insulin syringe, 1 unit equals 0.01 mL, or 200 mcg total blend: 125 mcg GHK-Cu plus 25 mcg each of BPC-157, TB-500, and KPV. If your label uses a different ratio, the per-unit component math changes.

Why do KLOW unit calculators disagree?

Because KLOW is not standardized. Unit math depends on two things: the mass of each ingredient in the vial and the amount of diluent added. A 50/10/10/10 vial and a 50/15/15/10 vial produce different component amounts per syringe unit even if both are called KLOW.

Multi-peptide blend · research-market term

What is KLOW peptide?

Q: What is KLOW peptide?

In current peptide-market usage, KLOW peptide usually means a non-standardized four-component blend containing BPC-157, TB-500, GHK-Cu, and KPV. It is not a single peptide sequence, and the exact mass ratio can vary by supplier.

Q: What is KLOW blend peptide?

KLOW blend peptide usually refers to a vial combining four separate research peptides: BPC-157, TB-500, GHK-Cu, and KPV. The evidence base belongs to the individual components, not to a standardized KLOW product.

Q: What is KLOW peptide dosage?

This page does not provide a KLOW peptide dosage or protocol. KLOW dosage searches often mix up two different concepts: a medical dose and reconstitution arithmetic. The arithmetic depends on the vial ratio and diluent volume; it does not recommend how much anyone should use.

Q: What are KLOW peptide benefits?

KLOW peptide benefits are usually marketed around tissue repair, collagen support, inflammation modulation, and recovery. Those claims are extrapolated from the individual components: BPC-157, TB-500, GHK-Cu, and KPV. KLOW as a blend has not been established as safe or effective by FDA review.

Q: Is KLOW the same as GLOW peptide?

Usually no. GLOW peptide commonly refers to a three-part blend of GHK-Cu, BPC-157, and TB-500. KLOW usually adds KPV, making it a four-part blend, although supplier labels can vary.

Q: Is KLOW FDA-approved?

No. KLOW is not FDA-approved for any indication. Its common components are also not approved as a KLOW blend. FDA's April 22, 2026 503A update removed BPC-157, KPV, TB-500, and injectable GHK-Cu from Category 2 because nominations were withdrawn, with PCAC review dates planned for some components. Removal from Category 2 is not FDA approval and does not itself authorize compounding.

Commonly labeled as: BPC-157 + TB-500 + GHK-Cu + KPV in one vial

KLOW peptide is usually a four-component research blend containing BPC-157, TB-500, GHK-Cu, and KPV. KLOW is not a single peptide sequence, and exact ratios vary, so the vial label and certificate of analysis matter more than the acronym.

Class: Combination blend label, not a single molecule
Most common components: BPC-157 · TB-500 · GHK-Cu · KPV^[1]
Common total vial mass: 80 mg total in many "KLOW 80" labels^[1]
Common ratio examples: 50/10/10/10 or 50/15/15/10, supplier-dependent^[1]
FDA status: Not approved as a blend; components are not FDA-approved for KLOW use^[6]
Klotho status: Separate from Klotho-derived peptide KP1 research^[7]
Typical reconstitution solvent: Bacteriostatic water (0.9% benzyl alcohol)
Primary math risk: Units change when component ratios or diluent volume change

Educational reference only. KLOW has no FDA-approved clinical use. This page does not recommend a dose, cycle, indication, source, or route. It explains the label, component mechanisms, regulatory context, and concentration arithmetic so users do not confuse "units" with ingredient mass.

Last reviewed April 28, 2026 by the Enhanced Health Editorial Team. See the editorial policy.

Quick answers for KLOW search terms

What is KLOW peptide? Usually a BPC-157 + TB-500 + GHK-Cu + KPV blend, not a single molecule.
What is KLOW? A non-standardized blend label used by peptide vendors and search pages.
KLOW blend peptide / KLOW blend. Same search intent: people are usually asking which ingredients are in the vial and how the ratio affects the math.
KLOW dosage / KLOW peptide dosage. This page does not provide a dose or protocol. It covers reconstitution arithmetic because "units" depend on vial ratio and diluent volume.
KLOW peptide benefits. Benefits are marketed from the component mechanisms; KLOW itself has not been established as safe or effective by FDA review.
GLOW peptide vs KLOW peptide. GLOW usually means GHK-Cu + BPC-157 + TB-500. KLOW usually adds KPV.

What KLOW is

KLOW is best understood as a blend name. Search results and vendor pages commonly use it for an expanded "Wolverine" style stack: BPC-157 plus TB-500, with GHK-Cu and KPV added. That matters because the evidence base belongs to the individual compounds, not to a standardized KLOW molecule.

There is no single peer-reviewed KLOW sequence, no universally accepted ratio, and no FDA-approved KLOW product. If a vial says "KLOW 80," it usually means 80 mg total peptide blend, but the component breakdown still needs to be verified on the label or certificate of analysis.

KLOW blend peptide component map

BPC-157. Synthetic 15-amino-acid gastric pentadecapeptide studied mostly in preclinical tissue-repair and gastrointestinal-protection models. Published animal pharmacokinetic data report a short elimination half-life under 30 minutes after IV/IM administration.^[2]
TB-500. Research-market name for a thymosin beta-4 related peptide or fragment. The relevant thymosin beta-4 literature centers on actin binding, cell migration, angiogenesis, and wound-healing biology.^[3]
GHK-Cu. Gly-His-Lys copper complex studied for dermal remodeling, collagen and glycosaminoglycan synthesis, metalloproteinase modulation, and wound-healing support. Topical cosmetic use is separate from injectable research use.^[4]
KPV. Lys-Pro-Val, the C-terminal tripeptide fragment of alpha-MSH. Preclinical work describes PepT1-mediated uptake and inhibition of inflammatory signaling pathways including NF-kappaB and MAP kinase.^[5]

KLOW peptide benefits: claims vs evidence

Searches for "KLOW peptide benefits" usually point to marketing claims around recovery, tissue repair, collagen support, inflammation modulation, and skin or gut support. Those claims are extrapolated from the individual ingredients. A finished KLOW blend has not been established through FDA review as safe, effective, or clinically beneficial.

Tissue-repair claims are usually tied to BPC-157 and TB-500 preclinical literature, not to a standardized KLOW human trial.
Collagen and skin-remodeling claims are usually tied to GHK-Cu literature, especially dermal and topical/cosmetic research.
Inflammation-modulation claims are usually tied to KPV's preclinical anti-inflammatory signaling work.
Blend claims require extra caution because a fixed blend changes all ingredients at once and may have different stability, tolerability, and quality-control issues than separate vials.

KLOW vs Klotho peptide

Some current search results use "KLOW peptide" to mean a synthetic fragment of the Klotho protein. That is a different topic. Klotho-derived peptide research includes molecules such as KP1, a 30-amino-acid Klotho-derived peptide studied preclinically for TGF-beta signaling and kidney fibrosis.^[7]

For searchers, the practical distinction is simple: KLOW blend usually means BPC-157 + TB-500 + GHK-Cu + KPV, while Klotho-derived peptide means a peptide fragment from the Klotho protein family. Do not assume one label describes the other.

KLOW vs GLOW peptide

GLOW peptide is a related blend term that commonly refers to three ingredients: GHK-Cu, BPC-157, and TB-500.^[8] KLOW usually builds on that pattern by adding KPV. In other words, GLOW is commonly a three-part blend; KLOW is commonly a four-part blend.

This difference matters for unit math. A 70 mg GLOW label such as 50/10/10 is not interchangeable with an 80 mg KLOW label such as 50/10/10/10. The total concentration, the per-unit amount, and the ingredient split all change.

Regulatory status

KLOW is not FDA-approved. Its common components are not approved together as a KLOW blend, and none of the research-vendor KLOW labels should be treated as an FDA-reviewed drug product.

FDA 503A update. The FDA's April 22, 2026 bulk-substances update says BPC-157, KPV, TB-500, and injectable-route GHK-Cu were removed from Category 2 because nominations were withdrawn. The same update notes planned PCAC consultation for BPC-157, KPV, and TB-500 on July 23, 2026, and GHK-Cu before the end of February 2027.^[6]
Not approval. Removal from Category 2 is not FDA approval, not a finding that a substance is safe or effective, and not automatic permission to compound.
Blend-specific gap. Even if an individual component is discussed by PCAC, that does not establish a reviewed KLOW blend formulation, ratio, route, stability profile, or indication.

KLOW dosage vs reconstitution math

Searches for "KLOW dosage" and "KLOW peptide dosage" often mix up medical dosing with vial arithmetic. This page gives math only — no dose recommendation. KLOW unit calculations require two facts: the mass of each component in the vial and the diluent volume added. The examples below use a common 80 mg total label: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV.

Example 1 · 80 mg total blend + 4 mL bac water total concentration = 80 mg / 4 mL = 20 mg/mL
1 unit = 0.01 mL = 200 mcg total blend
per unit, if label is 50/10/10/10:
→ GHK-Cu = 125 mcg
→ BPC-157 = 25 mcg
→ TB-500 = 25 mcg
→ KPV = 25 mcg

Example 2 · 80 mg total blend + 2 mL bac water total concentration = 80 mg / 2 mL = 40 mg/mL
1 unit = 0.01 mL = 400 mcg total blend
per unit, if label is 50/10/10/10:
→ GHK-Cu = 250 mcg
→ BPC-157 = 50 mcg
→ TB-500 = 50 mcg
→ KPV = 50 mcg

Example 3 · 80 mg total blend + 5 mL bac water total concentration = 80 mg / 5 mL = 16 mg/mL
1 unit = 0.01 mL = 160 mcg total blend
per unit, if label is 50/10/10/10:
→ GHK-Cu = 100 mcg
→ BPC-157 = 20 mcg
→ TB-500 = 20 mcg
→ KPV = 20 mcg

If the label is 50/15/15/10, a 4 mL reconstitution still gives 200 mcg total blend per unit, but the component split becomes 125 mcg GHK-Cu, 37.5 mcg BPC-157, 37.5 mcg TB-500, and 25 mcg KPV per unit. The total-unit math stays simple; the component math changes with the ratio.

Storage and handling

Lyophilized powder. Store sealed per the supplier certificate of analysis, commonly refrigerated at 2–8 °C or frozen at -20 °C.
After reconstitution. Refrigerate at 2–8 °C. Bacteriostatic water is commonly used for multi-draw preparations; sterile water is usually single-draw.
GHK-Cu sensitivity. Copper-peptide complexes are more sensitive to light, oxidation, and repeated freeze-thaw. Protect mixed vials from light and discard if the solution changes color, turns cloudy, or shows particles.
Blend limitation. A blend prevents independent adjustment of the four ingredients. Changing the draw volume changes all four components at once.

Frequently asked questions

What is KLOW peptide?

Usually a four-component blend of BPC-157, TB-500, GHK-Cu, and KPV. It is a vendor or market label, not a single peptide sequence. Exact ratios vary by label.^[1]

What is KLOW?

KLOW is a non-standardized blend label. Most current KLOW references mean an expanded GLOW-style blend that adds KPV to GHK-Cu, BPC-157, and TB-500.

What is KLOW blend peptide?

A KLOW blend peptide vial usually combines four separate research peptides: GHK-Cu, BPC-157, TB-500, and KPV. The evidence and regulatory status should be checked component by component.

What is KLOW peptide dosage?

This page does not provide a KLOW peptide dosage, cycle, or protocol. It gives reconstitution arithmetic only. Units on a syringe are volume, so the per-unit ingredient amount depends on the vial ratio and how much diluent was added.

What are KLOW peptide benefits?

Marketed benefits usually include recovery, tissue repair, collagen support, skin remodeling, and inflammation modulation. Those are extrapolated from the component literature; KLOW as a blend has not been established as safe or effective by FDA review.

Is KLOW the same as Wolverine Blend?

No. Wolverine Blend usually means BPC-157 + TB-500. KLOW usually adds GHK-Cu and KPV to that two-part base.

Is KLOW the same as GLOW peptide?

No. GLOW peptide usually means GHK-Cu + BPC-157 + TB-500. KLOW usually adds KPV, making it a four-part blend. Always verify the label because blend names are not standardized.^[8]

Is KLOW the same as a Klotho peptide?

Usually no. Klotho-derived peptides such as KP1 are separate research molecules derived from the Klotho protein. They are not the same as a four-component KLOW blend.^[7]

How do I calculate units for a KLOW vial?

Divide each component's mass by the diluent volume, then multiply by 0.01 mL per syringe unit. For an 80 mg 50/10/10/10 vial with 4 mL bac water, 1 unit is 200 mcg total blend: 125 mcg GHK-Cu and 25 mcg each of BPC-157, TB-500, and KPV.

Is KLOW FDA-approved?

No. KLOW is not FDA-approved, and the common components are not approved as a combined KLOW product. The April 22, 2026 FDA 503A update changed category status for several components, but that is not approval and not a blend-specific review.^[6]

Why do KLOW calculators disagree?

Because they may assume different vial ratios or different reconstitution volumes. A 50/10/10/10 vial and a 50/15/15/10 vial produce different per-unit component amounts even if both say "KLOW 80."

References and context

The KLOW Peptide. Market-context page describing KLOW as a four-peptide blend and noting common 80 mg total vial ratios. This is cited only for current market usage, not as clinical evidence. theklowpeptide.com
Xu C, Sun L, Ren F, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. Frontiers in Pharmacology 2022
Xing Y, Ye Y, Zuo H, Li Y. Progress on the function and application of thymosin β4. Front Endocrinol (Lausanne), 2021;12:767785. PMC8724243
Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Res Int, 2015. PMC4508379
Kannengiesser K, Maaser C, Heidemann J, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Inflamm Bowel Dis / Gastroenterology 2008. PubMed 18061177
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. Updated April 22, 2026. FDA 503A categories update
Yuan Q, Ren Q, Li L, et al. A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling. Nat Commun. 2022;13:438. PubMed 35064106
GLOW Peptide. Market-context page describing GLOW as a three-peptide blend containing GHK-Cu, BPC-157, and TB-500. This is cited only for current market usage, not as clinical evidence. glowpeptide.org

Track blend labels without losing the math

Enhanced Health keeps vial concentrations, component notes, dose history, and lab context together on iPhone. Local-first. No ads. Research/educational framing throughout.

Download on the App Store